Navigation Links
Despite missing primary efficacy endpoint, ATOMIC-AHF identifies positive trends
Date:9/2/2013

AMSTERDAM, The Netherlands Omecamtiv mecarbil, a cardiac myosin-activator, did not achieve its primary efficacy endpoint in reducing dyspnoea (shortness of breath) in patients with acute heart failure, according to the results of the phase II ATOMIC-AHF (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure) study.

However, a cohort which received the highest dose of the drug showed greater dyspnoea relief compared with placebo, and there were also other favourable dose and concentration-related trends, noted lead investigator John R. Teerlink, MD, Professor of Clinical Medicine at the University of California San Francisco and Director of Heart Failure at the San Francisco Veterans Affairs Medical Center, USA.

"The study was a real success for its purpose, as a dose-finding, safety and tolerability study," he said. "The main objective of ATOMIC-AHF was to investigate the pharmacokinetics and tolerability of intravenous omecamtiv mecarbil in the acute heart failure (AHF) population, and like most Phase II studies, it was not powered or designed around the efficacy endpoint," he explained.

"We are pleased to see as much efficacy signal as was apparent, and the study provides essential data to inform the dosing regimen for future Phase 3 trials of the intravenous formulation."

ATOMIC-AHF enrolled 613 patients with left ventricular systolic dysfunction who were acutely hospitalised with dyspnoea at rest or minimal exertion.

The subjects, from 106 sites in North America, Europe and Australia, were randomly assigned to receive 48 hours of intravenous placebo or omecamtiv mecarbil (OM) in 3 ascending dose cohorts designed to achieve plasma concentrations of 115, 230, and 310 ng/mL.

The primary efficacy endpoint was the effect on dyspnoea at 6, 24 and 48 hours, with secondary endpoints of safety, tolerability, pharmacokinetics, and echocardiographic indices of cardiac funct
'/>"/>

Contact: ESC Press Office
press@escardio.org
44-773-005-7146
European Society of Cardiology
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Many Still Tanning, Despite Dangers, Survey Finds
2. Despite less play, childrens use of imagination increases over 2 decades
3. Despite hardships, black men in urban communities are resilient, MU researcher says
4. Despite clear benefits, heart failure clinics are rarely utilized
5. Seniors Creativity Can Thrive Despite Dementia
6. Undertreatment of common heart condition persists despite rapid adoption of novel therapies
7. Ethnic disparities in breast cancer survival remain despite socioeconomic similarities
8. Pneumonia remains the leading killer of children despite decline in global child deaths
9. Despite FDA Warning, Sports Supplements Still Available Online: Study
10. Despite hype, costly prostate cancer treatment offers little relief from side effects
11. Many U.S. Teens at Risk for Suicide Despite Treatment: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... July 28, 2015 , ... ... that Schneider Electric has completed its upgrade and expansion of its ... with more than 170,000 employees in 134 countries supplying a wide range of ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... of Directors has authorized the Company, from time to time and depending on ... value of up to $25 million. Repurchases will be made in open market ...
(Date:7/28/2015)... ... July 28, 2015 , ... Women fear developing Alzheimer's disease ... that cancer, heart attack, and stroke are treatable, but there is little an individual ... is to take part in a clinical trial, reports the July 2015 Harvard ...
(Date:7/28/2015)... ... July 28, 2015 , ... A new study published by ... Study Says " sheds light on a possible new treatment option for people living ... of regular HBOT sessions, at least five per week, patients experienced a significant decrease ...
(Date:7/28/2015)... ... ... Most employers have been using multi-tier prescription drug plans for many years, but ... in the use of 4-tier plans, which typically cover the highest cost drugs, as ... to continue, according to UBA. , UBA’s survey finds that, since 2009, the number ...
Breaking Medicine News(10 mins):Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 2Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 4Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 2Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 3Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 4Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 5
... LOS ANGELES, May 29 Writers and producers,from ... others were honored,at the 2008 Voice Awards last ... Administration (SAMHSA), hosted by award-winning actor and,mental health ... at Paramount Studios in Los Angeles., Winners ...
... ALOKA announced today new compact,ProSound ultrasound Systems which ... Federation of Societies for Ultrasound in Medicine and ... in Timisoara, Romania. The ProSound 2 is a,portable ... functions. High image quality technologies developed for,the premium ...
... The gene that allows fireflies to flash is helping ... UT Southwestern Medical Center researchers are among the first to ... used to determine the effectiveness of cancer drugs that choke ... requires a substrate called luciferin to be added to the ...
... More northern women feel bloating and,gurgling than their southern ... it at any one time, according to a TNS ... and Yorkshire and Humberside fared the,worst (71%), with Greater ... bloated feelings. And 61% of British women experience feeling,bloated, ...
... receiving the necessary symptom management that they require to ... its treatment, or both, according to a leading professor ... million people around the world (10 million in the ... newly diagnosed with cancer can expect to live at ...
... July 10 Cash Dividend ... - Preliminary Proxy Results, WALNUT CREEK, Calif., May 28 ... and the,preliminary proxy results at its 2008 Annual Meeting of Stockholders., ... dividend on common shares of $0.14 per share payable July,10, 2008 to ...
Cached Medicine News:Health News:SAMHSA Honors 'The Sopranos,' 'Monk,' 'Dirt' at Star-Studded Voice Awards in Los Angeles 2Health News:SAMHSA Honors 'The Sopranos,' 'Monk,' 'Dirt' at Star-Studded Voice Awards in Los Angeles 3Health News:SAMHSA Honors 'The Sopranos,' 'Monk,' 'Dirt' at Star-Studded Voice Awards in Los Angeles 4Health News:ALOKA to Unveil a New Compact 'ProSound' Diagnostic Ultrasound System 2Health News:Fireflies' glow helps UT Southwestern researchers track cancer drug's effectiveness 2Health News:Fireflies' glow helps UT Southwestern researchers track cancer drug's effectiveness 3Health News:North South Divide Exists in UK Digestive Health 2Health News:North South Divide Exists in UK Digestive Health 3Health News:Cancer survivors are living 'in limbo' with unmet needs for care 2Health News:Cancer survivors are living 'in limbo' with unmet needs for care 3Health News:Longs Drug Stores Corporation Announced at Its Annual Meeting of Stockholders 2
(Date:7/28/2015)... FORT WORTH, Texas , July 28, 2015 /PRNewswire/ ... Report "Global Dermatology Devices Market by Type (Dermatology Treatment ... MRI, CT), Dermatoscopes, Microscopes]), by Application, by Geography - ... market is expected to reach $11.88 billion by 2019, ... Browse through the TOC of Global Dermatology ...
(Date:7/28/2015)... , July 28, 2015 Research ... addition of the "Global Hearing Aids Market ... The global hearing aids market to grow ... 2014-2019. Factors such as changing ... driving market growth. The market has witnessed immense ...
(Date:7/28/2015)... 2015   CSL Behring announced today ... Authorization Application (MAA) for the company,s investigational long-acting ... recombinant albumin (rIX-FP) for the prophylaxis and treatment ... Upon Swissmedic approval, rIX-FP will provide hemophilia B ... intervals up to 14 days. ...
Breaking Medicine Technology:Global Dermatology Devices Market to be Worth $11.88 Billion by 2019 2Global Dermatology Devices Market to be Worth $11.88 Billion by 2019 3Global Hearing Aids Market 2015-2019 with G N Store Nord, Sonova Holdings & William Demant Dominating 2Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 2Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 3Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 4
... Phosphagenics,Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) today ... undertake a Phase 1 transdermal,oxycodone clinical trial aimed ... management product. Phosphagenics has submitted all necessary ... be conducted at CMAX - an independent clinical ...
... Phase 2 clinical development, PRINCETON, N.J., Sept. ... in the discovery and development of novel,small molecule ... 2a,clinical study of PS433540, the company,s lead internal ... receptor antagonist,(DARA) that is being developed as a ...
Cached Medicine Technology:Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 4Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 5
... Intelli-Storeroom™ was developed to create physically secured ... and exits are converted to RFID portals. ... readers and antennas by VerdaSee's Field Engineering ... to assets that are to be tracked. ...
... Mobile Aspects provides hospitals ... products to track all their ... Our RFID systems remove all ... items and people accurately. iRIS, ...
The WatchMate LC model is a cost-effective solution for monitoring a single exit, and provides local notification of an alarm....
... AgileTrac Surgical Services is a Web-based ... to track, manage, and measure patient flow ... process, from admission to discharge. AgileTrac collects ... of care delays your patient might experience. ...
Medicine Products: